


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-48 (canceled)

49.(currently amended) A compound having the formula



wherein X is O; Y is O; m, n, p and q are each 0; ~~R<sup>4</sup>, R<sup>5</sup>, R<sup>7</sup> and R<sup>9</sup>~~ R<sub>4</sub>, R<sub>5</sub>, R<sub>7</sub> and R<sub>9</sub> are each H; ~~R<sup>8</sup>~~ R<sub>8</sub> is phosphono; ~~R<sup>6</sup>~~ R<sub>6</sub> is selected from OH, CO<sub>2</sub>H and CONH<sub>2</sub>; and ~~R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>~~ R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are independently selected from C<sub>6</sub> acyl groups and C<sub>10</sub> acyl groups;

and pharmaceutically acceptable salts thereof.

50.(currently amended) A compound according to claim 49, wherein at least one of ~~R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>~~ R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> is a C<sub>6</sub> acyl group and at least one other of ~~R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>~~ R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> is a C<sub>10</sub> acyl group.

51.(currently amended) A compound in accordance with claim 49, wherein two of ~~R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>~~ R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are C<sub>6</sub> acyl groups.

52.(currently amended) A compound in accordance with claim 49, wherein two of ~~R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>~~ R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are C<sub>10</sub> acyl groups.

53.(currently amended) A compound in accordance with claim 49, wherein ~~R<sup>6</sup>~~ R<sub>6</sub> is CO<sub>2</sub>H.

54.(currently amended) A compound in accordance with claim 53, wherein ~~R<sup>1</sup>~~ R<sub>1</sub> is a C<sub>6</sub> acyl group and ~~R<sup>2</sup> and R<sup>3</sup>~~ R<sub>2</sub> and R<sub>3</sub> are both C<sub>10</sub> acyl groups.

55.(currently amended) A compound in accordance with claim 53, wherein ~~R<sup>3</sup>~~ R<sub>3</sub> is a C<sub>10</sub> acyl group and ~~R<sup>1</sup> and R<sup>2</sup>~~ R<sub>1</sub> and R<sub>2</sub> are both C<sub>6</sub> acyl groups.

56.(currently amended) A compound in accordance with claim 53, wherein ~~R<sup>1</sup>~~ R<sub>1</sub> is a C<sub>10</sub> acyl group and ~~R<sup>2</sup> and R<sup>3</sup>~~ R<sub>2</sub> and R<sub>3</sub> are both C<sub>6</sub> acyl groups.

57.(currently amended) A compound in accordance with claim 53, wherein ~~R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup>~~ R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are all C<sub>6</sub> acyl groups.

~~59~~ 58.(currently amended) A pharmaceutically acceptable ~~sale~~ salt in accordance with claim 49.

~~60~~ 59.(currently amended) A pharmaceutically acceptable salt in accordance with claim ~~60~~ 50.

~~61~~ 60.(currently amended) A pharmaceutical composition comprising a compound of claim 49 and a pharmaceutically acceptable carrier.

~~62~~ 61.(currently amended) A method for enhancing the immune response of a mammal comprising administering to the mammal an effective amount of a compound of claim 49.